Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations.

Tiacci E, Spanhol-Rosseto A, Martelli MP, Pasqualucci L, Quentmeier H, Grossmann V, Drexler HG, Falini B.

Leukemia. 2012 Mar;26(3):554-7. doi: 10.1038/leu.2011.238. Epub 2011 Sep 9. No abstract available.

PMID:
21904384
2.

Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model.

Hollink IH, Feng Q, Danen-van Oorschot AA, Arentsen-Peters ST, Verboon LJ, Zhang P, de Haas V, Reinhardt D, Creutzig U, Trka J, Pieters R, van den Heuvel-Eibrink MM, Wang J, Zwaan CM.

Leukemia. 2012 Feb;26(2):371-3. doi: 10.1038/leu.2011.210. Epub 2011 Aug 12. No abstract available.

PMID:
21836609
3.

Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia.

Gale RE, Lamb K, Allen C, El-Sharkawi D, Stowe C, Jenkinson S, Tinsley S, Dickson G, Burnett AK, Hills RK, Linch DC.

J Clin Oncol. 2015 Jun 20;33(18):2072-83. doi: 10.1200/JCO.2014.59.2022. Epub 2015 May 11.

PMID:
25964253
4.

BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.

Stewart HJ, Horne GA, Bastow S, Chevassut TJ.

Cancer Med. 2013 Dec;2(6):826-35. doi: 10.1002/cam4.146. Epub 2013 Oct 31.

5.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.

Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton Sd, Revel Td, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C.

Leukemia. 2012 Jun;26(6):1247-54. doi: 10.1038/leu.2011.382. Epub 2012 Jan 13.

PMID:
22289988
6.

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.

Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M.

J Clin Oncol. 2011 Jul 20;29(21):2889-96. doi: 10.1200/JCO.2011.35.4894. Epub 2011 Jun 13.

PMID:
21670448
7.

Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.

Devillier R, Gelsi-Boyer V, Brecqueville M, Carbuccia N, Murati A, Vey N, Birnbaum D, Mozziconacci MJ.

Am J Hematol. 2012 Jul;87(7):659-62. doi: 10.1002/ajh.23211. Epub 2012 Apr 25.

8.

Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?

Mattsson G, Turner SH, Cordell J, Ferguson DJ, Schuh A, Grimwade LF, Bench AJ, Weinberg OK, Marafioti T, George TI, Arber DA, Erber WN, Mason DY.

Haematologica. 2010 Apr;95(4):670-3. doi: 10.3324/haematol.2009.011817. Epub 2009 Dec 16.

9.

Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor.

Papadaki C, Dufour A, Seibl M, Schneider S, Bohlander SK, Zellmeier E, Mellert G, Hiddemann W, Spiekermann K.

Br J Haematol. 2009 Feb;144(4):517-23. doi: 10.1111/j.1365-2141.2008.07488.x. Epub 2008 Nov 26.

PMID:
19055671
10.

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G.

Blood. 2006 May 15;107(10):4011-20. Epub 2006 Feb 2.

11.

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.

Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N, Naoe T.

Blood. 2005 Oct 15;106(8):2854-61. Epub 2005 Jun 30.

12.

Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.

Berenstein R, Blau IW, Suckert N, Baldus C, Pezzutto A, Dörken B, Blau O.

J Exp Clin Cancer Res. 2015 May 22;34:55. doi: 10.1186/s13046-015-0173-2.

13.

GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations.

Perugini M, Iarossi DG, Kok CH, Cummings N, Diakiw SM, Brown AL, Danner S, Bardy P, Bik To L, Wei AH, Lewis ID, D'Andrea RJ.

Leukemia. 2013 Jul;27(7):1588-92. doi: 10.1038/leu.2012.346. Epub 2012 Nov 28. No abstract available.

PMID:
23187294
14.

Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.

Marková J, Michková P, Burčková K, Březinová J, Michalová K, Dohnalová A, Maaloufová JS, Soukup P, Vítek A, Cetkovský P, Schwarz J.

Eur J Haematol. 2012 Feb;88(2):128-35. doi: 10.1111/j.1600-0609.2011.01716.x. Epub 2011 Nov 17.

PMID:
21967546
15.

Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.

Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, Macleod RA, Nicoletti I, Mannucci R, Pucciarini A, Bigerna B, Martelli MF, Mecucci C, Drexler HG, Falini B.

Leukemia. 2005 Oct;19(10):1760-7.

PMID:
16079892
16.

Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.

Falini B.

Cancer Treat Res. 2010;145:149-68. doi: 10.1007/978-0-387-69259-3_9.

PMID:
20306250
17.

Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E, Haferlach T.

Blood. 2011 Jan 27;117(4):1109-20. doi: 10.1182/blood-2010-08-299990. Epub 2010 Oct 28. Review.

18.

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.

Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S, Figueroa ME, Zeilemaker A, Melnick A, Löwenberg B, Valk PJ, Delwel R.

Blood. 2012 Jun 14;119(24):5824-31. doi: 10.1182/blood-2011-07-367961. Epub 2012 Apr 5.

19.

DNMT3A mutations in acute myeloid leukemia: impact on low-risk patients with CEBPA mutations.

Masuda S.

J Clin Oncol. 2011 Dec 1;29(34):4592-3; author reply 4593-4. doi: 10.1200/JCO.2011.38.2127. Epub 2011 Oct 31. No abstract available.

PMID:
22042957
20.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020

Supplemental Content

Support Center